Ipilimumab vs Lenvatinib Mesylate
Ipilimumab vs Lenvatinib Mesylate: Overview
This comparison examines the pharmacological differences between Ipilimumab and Lenvatinib Mesylate.
Mechanism of Action
Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.
Pharmacokinetics
Half-life: Ipilimumab β 14.7 days.
Chemical Properties
Type: Ipilimumab β Antibody; Lenvatinib Mesylate β Small molecule.